Breakthrough Therapy Designation is a program created by the U.S. Food and Drug Administration (FDA) to expedite the development and review of new drugs that treat serious or life-threatening conditions. Specifically, it aims to accelerate the availability of therapies that demonstrate substantial improvement over existing treatments.